


T cell Tolerance: an overview

Immunity and Infection BSc.
Module 3

Dr Nicola Rogers
January 3rd 2013

Autoreactive T cells are present in normal immune system



- Originally believed that T cells developing in the thymus are deleted if they recognise “self” – thus preventing autoimmunity
- Thymic negative selection is not 100%

Healthy individuals

Whilst many autoreactive cells are deleted, numerous self-reactive T cells are present in healthy subjects.

Eg: MBP-specific CD4⁺ in healthy individuals as well as MS patients

- activation status different

Eg: Up to 30% of population thought to carry self-reactive antibodies

- <1% develop SLE


Breakdown in tolerance - consequences

Failure of these tolerance mechanisms may result in a response to:


- Innocuous non-self antigens
 - » Allergy
- Self
 - » Autoimmunity

Central and Peripheral tolerance

Central - due to thymic deletion





Peripheral - due to mechanisms operative in lymphoid and peripheral tissues



Tolerance mechanisms


Central

- Thymic deletion
- Expression of Aire



Peripheral

- Anergy
- Deletion
- Ignorance
- Regulation



Mechanisms of central tolerance

What is central T cell tolerance?

- Deletion of T cells that recognise self-antigen in the thymus

How is it achieved?

- Thymic selection/deletion
- Aire



T cell repertoire selection

- Each T cell creates its own TCR by unique gene rearrangements
- Development of TCR repertoire is independent of antigen.
- Therefore some TCR will be:
 - strongly self-MHC/p reactive (high avidity)
 - unable to bind to self MHC/p (very low/no avidity)

So:

- How is MHC restriction guaranteed?
- How is autoimmunity controlled?

T cell repertoire selection

- Thymocytes undergo three selection processes in the thymus
 - β -selection
 - Positive selection
 - Negative selection



T cell repertoire selection

- Thymocytes undergo three selection processes in the thymus
 - β -selection
 - » Pre-TCR check point
 - » Is the β chain functional?
 - Positive selection
 - » self restriction
 - Negative selection
 - » Eliminates “danger”



β -Repertoire selection

Pre TCR checkpoint (β selection):


Is the new β chain functional?

YES

NO →




- cell survival
- cell division
- TcR α gene rearrangement
- differentiation to CD4⁺8⁺TCR $\alpha\beta$ ⁺



*Death by
apoptosis*



Positive Selection

- Selection for thymocytes bearing receptors capable of binding **self-MHC** molecules which results in **Self MHC-restriction**
- Selected for “usefulness”
- Cells that fail positive selection are eliminated within the thymus, they **die by neglect**




Negative Selection


- Selection that **eliminates** thymocytes bearing high-affinity **receptors for self-MHC** molecules alone or self-antigen presented by self MHC
- Selects against “**danger**” ie: autoreactivity
- Results in Self tolerance
- Results in Central tolerance




Repertoire Selection- summary




Only 5% of thymocytes survive selection






AIRE

- *Aire*: Autoimmune regulatory gene
 - *Aire*^{-/-} mice
- Regulates the presentation of peripheral self-antigen in the thymus
 - tissue-specific antigens
 - developmental antigens



- APECED (autoimmune polyendocrinopathy, candidiasis-ectodermal dystrophy) ; APS-1

Mechanisms of peripheral tolerance



Deletion

T cells specific for self-antigen are deleted

- Chronic/persistent stimulation with self-antigen
- High/excessive dose of self-antigen
- Mechanisms:
 - Active: Fas-FasL interaction
 - Passive: cytokine (IL-2) deprivation

Anergy

“a state of long-lasting, partial or total unresponsiveness induced by partial activation”

Induced by:

- Ag recognition (signal 1) in the absence of costimulation (signal 2)
 - Eg: CD80/86
- Ligation of co-inhibitors
 - Eg: CTLA-4
- Full signalling but without division
- *In vitro*: well defined (T cell clones)
- *In vivo*: difficult to distinguish from deletion/exhaustion

T cell: APC interaction


Molecular interactions during T cell activation

1: Cognate TCR:MHC/peptide (signal 1)


2: Costimulation (signal 2)

3: Adhesion

4: IL-2




Signal 1 and Signal 2




Recognition without costimulation

Signal 1 + Signal 2



Proliferation
Differentiation
Effector Function

No Signal 2




Cell dies or
ignores antigen


Absence of costimulation = Tolerance

The type of antigen presentation that occurs determines the outcome of activation or tolerance:


- Costimulation +ve cells:
 - mature DC
 - Macrophages
 - Activated B cells
- Costimulation -ve cells:
 - Fibroblasts
 - Epithelial cells
 - Immature DC (low level expression NOT -ve)




Conventional APC



DC




B cell




Macrophage

- Undergo maturation
- Constitutively express MHC class II molecules and CD80
- Induce T cell activation when mature
- Can induce T cell inactivation when immature

Non-conventional APC




Fibroblasts




Epithelial cells

- Fully differentiated
- MHC class II induced by inflammation
- Induce T cell **in-activation**
 - Role in peripheral tolerance to self antigen

The rat model




The graft is not rejected:
the graft is fully antigenic
but is not immunogenic
(allo-MHC express by
epithelial cells)




no immunosuppression
no rejection


The rat model



The “danger” hypothesis



Immature DC
Signal 1 only




Mature DC
Signals 1 & 2



- The immune system is activated when an antigen is associated with ‘danger/harm’
 - danger/harm results in DC maturation
- Activation state of DCs (immature vs mature) determines whether outcome is clonal expansion and effector function or abortive response


Coinhibition – negative costimulation

Signal 1 + Signal 2



Proliferation
Differentiation
Effector Function


Costimulatory molecule
binds **CTLA4**



Cell cycle arrest

Coinhibition – “negative costimulation”

- CTLA4 is not constitutively expressed
 - Expressed only after T cell activation
- CTLA4 has a higher affinity for CD80 and CD86 than does CD28
- CTLA4 expression is transient
 - Rapidly internalised
- Co-inhibitory molecule
 - Tolerance induction
 - Limiting the immune response
- Multiple mechanisms (CS lecture)




Function of anergic T cells

- Anergic T cells can persist *in vivo* for a long period of time
- Anergic T cells can exert suppressor function *in vitro* and *in vivo*
- Overlap with regulatory T cells?

Regulatory T cells

- First proposed in 1970 by Gershon.
- In 1970's and 1980's generation of suppressor hybridoma.
- Tolerance can be transferred with T cells in transplantation models.
- 1990's two important discoveries:
 - Regulatory cytokines (TGF- β and IL-10)
 - CD4⁺CD25⁺ T cells

The rat model



Treg families: induced and naturally occurring

Induced

in vitro and *in vivo*:

Anergic T cells

Tr1

Th3

CD8⁺CD28⁻

Naturally occurring:

CD4⁺CD25⁺

NK-T cells

CD4⁺CD25⁻

Treg families: induced and naturally occurring

Induced

in vitro and *in vivo*:

Anergic T cells

Tr1

Th3

CD8⁺CD28⁻

Naturally occurring:


CD4⁺CD25⁺

NK-T cells

CD4⁺CD25⁻

CD4⁺CD25⁺ T cells


Normal Mouse



Thymectomy 3-5
days after birth




Partially T cell
depleted mouse



Mouse has severe
polyautoimmune disease
including: gastritis,
thyroiditis, oophritis and
diabetes

CD4⁺CD25⁺ T cells




CD4⁺CD25⁺ T cells

- 5-10% of the CD4⁺ T lymphocytes in healthy adult mice and humans.
- Generated in the thymus
- Constitutively express
 - CD25
 - CTLA-4
 - GITR
 - Foxp3
- Hyporesponsive/anergic and suppressive both *in vivo* and *in vitro*.


Foxp3

- Scurfy mice: natural mutants, develop multisystemic autoimmune disease.
 - Deletion of FoxP3
 - lack CD4⁺CD25⁺ T regulatory cells
- IPEX syndrome: X – linked (Immunodysregulation, Polyendocrinopathy, Enteropathy)
 - Mutations in Foxp3 identified in 13/14 patients
 - Truncation of FoxP3 protein
 - Commonly presents in infants with severe diarrhea and failure to thrive
 - Death by 12months if untreated


The mechanisms of action of Treg....



The mechanisms of action of Treg....



The mechanisms of action of Treg....



CD4⁺CD25⁺

regulatory function in animal models

Autoimmunity

- Mice with EAE show significant improvement when infused with CD4⁺CD25⁺ T cells from naïve mice
 - Zhang X *et al* 2004. *Int Immunol*. 16:249-56
- The onset of diabetes in NOD mice can be delayed by transfer of CD4⁺CD25⁺ T cells from syngeneic NOD
 - Salomon B *et al* 2000. *Immunity*. 12:431-440

Are CD4⁺CD25⁺ important in human disease?

Goodpasture's Disease

- Loss of tolerance to type IV collagen (glomerular basement membrane and alveoli)
- Characterised by glomerulonephritis and occasionally pulmonary haemorrhage
- Symptoms rarely relapse+remit – patients enter complete remission and this coincides with the emergence of CD4⁺CD25^{hi} T cells specific for type IV collagen
 - Salama AD *et al* *Kidney Int* 2003 64:1685-1694.

Are CD4⁺CD25⁺ important in human disease?

Systemic Lupus Erythematosus (SLE)

- SLE patients have fewer peripheral CD4⁺CD25^{hi} T cells
 - Bagavant H *et al* 2004 *Scand. J of Immunol* 60:52-63
- CD4⁺CD25⁺ T cells from MRL/Mp mice (polygenic model of SLE) are resistant to CD4⁺ CD25⁺ T cell-mediated regulation
 - Monk *et al.* 2005. *Arthritis & Rheum* 52:1180

Are CD4⁺CD25⁺ important in human disease?

Rheumatoid Arthritis

- Studies have shown no difference in the number of peripheral CD4⁺CD25^{hi} T cells
- The synovium of inflamed joints contained higher frequencies of CD4⁺CD25^{hi} T cells than peripheral blood and these were anergic and suppressive *in vitro*
 - Cao D *et al* 2003 *Eur.J. Immunol* 33:215-223

CD4⁺CD25⁺

regulatory function in animal models

Transplantation Tolerance

- Rats can be made tolerant to cardiac allografts by transfer of CD4⁺CD25⁺ T cells from animals made tolerant to similar grafts with cyclosporin
 - Bach JF 2003 Nat Rev Immunol 3:189-198

Th3 cells – general features

- Th3 cells are central to mucosal immuno-regulation (GALT)
- Richman *et al* (1978) first demonstrated the induction of Ts cells by enteric antigen
- Many studies have characterised the cells responsible for GALT immunoregulation, including Th3 subset of CD4⁺ Tregs

Th3 cells – general features

- Mediate suppression by TGF- β
- Th3 cells provide help for IgA and suppress both Th1 and Th2 responses
- Differentiation from Th0 cells *in vitro* occurs in presence of TGF- β , IL-4, IL-10, anti-IL-12
- Th3 cells mediate ‘bystander suppression’
- “Eating” your way towards immunosuppression?

Tr1 cells – general features

- Tr1 cells specific for a variety of antigens arise *in vivo*; may also differentiate from naïve CD4⁺ T cells in presence of IL-10 *in vitro*
- Minimal proliferation: autocrine suppression by IL-10
- Require activation for regulatory function
- Regulate both Th1 and Th2 responses

Tolerance - Therapeutic strategies

- Chimaerism:
 - donor bone-marrow transfer – *i.v.*
 - induction of central tolerance
- Targeting T cell surface molecules
 - Costimulators/coinhibitors
- TCR targeting
- Cell-based therapies

Targeting co-inhibitors

- CTLA4Ig (abatacept)
- LEA29Y (belatacept)
 - recombinant extracellular domain of CTLA4 with mutation that increase 10fold binding to CD80 – antagonist
- Prevents the priming of antidonor T- and B-cell responses and can prolong islet allograft survival indefinitely under cover of sirolimus/tacrolimus in nonhuman primates
- Clinical trials suggest effectiveness with low side-effect in RA and renal transplantation

Targeting CD154

- Humanized anti-CD154 mAb hu5C8/Antova (Biogen)
- used in renal transplantation
 - several autoimmune indications
- These trials were discontinued because of :
 - multiple thromboembolic events (binding to platelets)
 - the failure to prevent rejection in five of seven patients receiving renal transplants
- IDEC Pharmaceuticals is also developing an anti-CD154 mAb (IDEC 131) with a current focus on autoimmune diseases

TCR targeting

Anti-CD3 mAbs

- OKT3 was the first FDA approved monoclonal antibody for use in kidney transplantation.
 - Severe side effects (cytokine storm)
- Humanized Fc receptor-nonbinding anti-CD3 antibodies (teplizumab) do not elicit a very toxic cytokine syndrome
 - have entered the clinic in both autoimmune disease and transplantation settings. Indications: transplantation GVHD, autoimmunity (diabetes, “Protégé” clinical trial phase II/III).
- Mechanism: generation of T regs

Cell-based therapies

- Adoptive transfer of regulatory T cells
 - Gagliani, N. *et al.* (2009). Autoimmune diabetic patients undergoing allogeneic islet transplantation: are we ready for a regulatory T-cell therapy?
Immunol Lett. Dec 2;127(1):1-7.
- Negative vaccination (tolerogenic DCs)
 - Hill, M. and Cuturi, M.C. (2010). Negative vaccination by tolerogenic dendritic cells in organ transplantation. *Curr Opin Organ Transplant.* Sep 24 *E-pub ahead of print.*